Skip to main content

Search articles in

Found 3,024 articles

  • About PACE

    About PACE

    • 22 Feb 2024
    • Editor

    PACE is a new approach to tackling one of the world’s most complex health challenges – antimicrobial resistance (AMR). PACE’s ambition is to work with the AMR community to help progress early-stage antimicrobial drug and diagnostic projects with greater speed, support and confidence – giving the best AMR innovations the greatest chance of success.

  • Why Counteroffers Aren’t Always the Answer, and Wh

    Why Counteroffers Aren’t Always the Answer, and What You Can Do to Make Them Worthwhile

    • 22 Feb 2024
    • Lucy Walters

    Counteroffers are often used as a quick way of incentivising employees to stay in their current organisation, rather than accepting a new job offer elsewhere. Whilst they may motivate employees to stay in their current role in the short-term, more often than not they fail to address the real reasons why the employee was looking for a new role in the first place.

  • About Kling Biotherapeutics

    About Kling Biotherapeutics

    • 22 Feb 2024
    • PharmiWeb Editor

    Kling Biotherapeutics boasts a fully owned IP portfolio featuring innovative platform technologies Kling-Select and Kling-Evolve. These cutting-edge technologies enable simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells.

  • About Mainz Biomed

    About Mainz Biomed

    • 21 Feb 2024
    • Editor

    The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

  • Innovative Trials unveils initiative to boost clin

    Innovative Trials unveils initiative to boost clinical trial patient retention in pediatric studies

    • 21 Feb 2024
    • Editor

    A new initiative designed to boost clinical trial patient retention in pediatric studies has been announced today (19 February) by Innovative Trials, global specialists in clinical trial patient recruitment and retention acceleration.

  • The 3rd Conference on Clinical Studies with Medical Devices and IVDs (CSMD2024)

    • 21 Feb 2024
    • PharmiWeb Editor

    CSMD2024 in London, UK, from May 29-30, 2024, for the 3rd Conference on Clinical Studies with Medical Devices and IVDs

  • What is Life Science?

    What is Life Science?

    • 21 Feb 2024
    • Lucy Walters

    Life science is a branch of science that focuses on the study of living organisms. It encompasses various disciplines such as genetics, zoology, botany, microbiology, ecology, biochemistry, and physiology.

  • BiVACOR® Receives $13 Million to Support Clinical

    BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart

    • 21 Feb 2024
    • Editor

    BiVACOR®, a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.

  • FDA Grants Priority Review to Merck’s Application

    FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

    • 21 Feb 2024
    • Editor

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel), followed by KEYTRUDA as a single agent for the treatment of patients with primary advanced or recurrent endometrial carcinoma.

  • AbbVie Announces Appointment of Robert A. Michael

    AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer

    • 21 Feb 2024
    • Editor

    AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO).

  • AION Labs, In Continued Partnership with BioMed X,

    AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules

    • 21 Feb 2024
    • Editor

    AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.

  • What Does a Therapy Specialist Do?

    What Does a Therapy Specialist Do?

    • 20 Feb 2024
    • Lucy Walters

    In this article, we dive deeper into the role of a Therapy Specialist, outlining some of the key responsibilities, benefits of this career path, and the essential requirements needed to succeed in this field.

  • About Terumo Blood and Cell Technologies

    About Terumo Blood and Cell Technologies

    • 20 Feb 2024
    • Editor

    Terumo Blood and Cell Technologies (Terumo BCT) is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions.

  • Opthea Appoints Arshad M. Khanani, MD, MA, FASRS,

    Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

    • 20 Feb 2024
    • Editor

    Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor.

  • AbbVie Unveils New Data from Robust Gastroenterolo

    AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)

    • 20 Feb 2024
    • Editor

    AbbVie (NYSE: ABBV) announced that 17 AbbVie-sponsored abstracts, including new data from its inflammatory bowel disease (IBD) portfolio, have been accepted for presentation at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.

  • European Commission Approves Pfizer’s VELSIPITY® f

    European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

    • 20 Feb 2024
    • Editor

    Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

  • Tagrisso with the addition of chemotherapy approve

    Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

    • 20 Feb 2024
    • Editor

    Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care. AstraZeneca’s has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).

  • About IGC Pharma

    About IGC Pharma

    • 19 Feb 2024
    • Editor

    IGC Pharma is pursuing innovative solutions to fight Alzheimer’s disease and related challenges. IGC Pharma’s portfolio comprises five assets, all with a singular mission – to transform the landscape of Alzheimer’s treatment.

  •  About Sartorius Stedim Biotech

    About Sartorius Stedim Biotech

    • 16 Feb 2024
    • Editor

    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically.

  • About Medigene AG

    About Medigene AG

    • 15 Feb 2024
    • Editor

    Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors.